Rooted in China, MedTecX is an innovative global medtech platform.

In February 2026, Uroconic partnered with Chinese medtech company MedTecX to launch UroVapor, a therapy for Benign Prostatic Hyperplasia (BPH), in selected LATAM markets.

MedTecX is a wholly foreign-owned enterprise dedicated to helping patients worldwide gain faster access to cutting-edge, cost-effective medical technologies that benefit the broader public. The company’s founding team includes industry experts with extensive experience in research and development, product commercialization, and investment in China and international markets.

Cutting-Edge Technologies

MedTecX’s platforms span multiple advanced technologies across a range of fields, including high-precision catheter interventions, neuromodulation, next-generation energy ablation, and implantable devices. These innovations address unmet clinical needs by combining global academic and industry advances to deliver breakthrough, world-class medical therapies to patients and customers worldwide.

Uroconic will be responsible for bringing UroVapor to several LATAM markets, managing activities from product registration through marketing and sales execution.

Want to learn more about how we can support your healthcare business? Contact us at contact.us@uroconic.com or use the form below.

Tags: News, Benign Prostatic Hyperplasia (BPH), Water Vapor Therapy, UroVapor